Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATENT: Nona-L-arginine for Vein Graft Disease
NCT00264706Phase 2Terminated
- Sponsor
- Lumen Therapeutics
- Start
- Mar 2005
- Primary completion
- Apr 2008
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nona-l-arginine in saphenous vein graft disease (SVGD), sponsored by Lumen Therapeutics. Started Mar 2005; status: terminated.
02
Drugs
nona-l-arginine
03
Conditions
saphenous vein graft disease (SVGD)
Beyond the preview
Go deeper on NCT00264706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00264706.